Related Experiment Video

Updated: Jun 12, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles

Han Hsi Wong1, Nicholas R Lemoine, Yaohe Wang

  • 1Centre for Molecular Oncology and Imaging, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; h.h.wong@qmul.ac.uk (H.H.W.); director@qmcr.qmul.ac.uk (N.R.L.).

Viruses
|June 15, 2010
PubMed

Insights

Oncolytic virus therapy shows promise for cancer treatment, but clinical success is hindered by complex interactions. This review explores challenges and advances in oncolytic virotherapy, focusing on adenoviruses.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Standard cancer therapeutics for advanced disease have limited efficacy and side effects.
  • Oncolytic viruses, which replicate in and lyse cancer cells, offer a targeted therapy approach.
  • The first oncolytic virus was approved for head and neck cancer in 2006.

Purpose of the Study:

  • To discuss the obstacles faced by oncolytic virotherapy.
  • To highlight recent advances in overcoming these challenges.
  • To focus on adenoviruses as a model for oncolytic virotherapy.

Main Methods:

  • Review of existing literature on oncolytic virotherapy.
  • Analysis of in vitro and animal model studies.
  • Examination of clinical trial outcomes and challenges.

Main Results:

  • Despite in vitro and animal model success, clinical efficacy of oncolytic viruses has been limited.
  • Complex interactions between the tumor microenvironment, virus, and host immune response are key challenges.
  • Adenoviruses show potential but face specific hurdles in clinical application.

Conclusions:

  • Oncolytic virotherapy holds significant therapeutic potential for cancer.
  • Overcoming multifaceted obstacles, including immune response and tumor microenvironment interactions, is crucial for clinical success.
  • Continued research and development, particularly with agents like adenoviruses, are needed to fully realize the benefits of oncolytic virotherapy.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...